UBS Maintains a 'Buy' on Incyte (INCY); Raising Numbers on Impressive Q1
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $120.16 -0.3%
Rating Summary:
17 Buy, 17 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
17 Buy, 17 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
UBS maintains a 'Buy' on Incyte (NASDAQ: INCY) price target raised from $22 to $26.
Analyst, Matthew Roden, said, "Key takeaways from Incyte’s 1Q12 [1] Patient and physician demand for Jakafi were higher than expected, and will drive upside to Street numbers; [2] datapoints suggest a long runway remains after strong initial demand (only 15% of accounts penetrated so far, 75% of patients are in community setting, which is still largely untapped); [3] payor coverage appears solid ahead of formulary determinations; [4] management has executed on the launch, and is continuing to manage expectations; and [5] good opex control illustrates discipline and lower financing risk."
FY12 EPS loss raised from (1.06) to (0.94) and FY13 (1.01) to (0.23).
For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.
Shares of Incyte closed at $21.93 yesterday.
Analyst, Matthew Roden, said, "Key takeaways from Incyte’s 1Q12 [1] Patient and physician demand for Jakafi were higher than expected, and will drive upside to Street numbers; [2] datapoints suggest a long runway remains after strong initial demand (only 15% of accounts penetrated so far, 75% of patients are in community setting, which is still largely untapped); [3] payor coverage appears solid ahead of formulary determinations; [4] management has executed on the launch, and is continuing to manage expectations; and [5] good opex control illustrates discipline and lower financing risk."
FY12 EPS loss raised from (1.06) to (0.94) and FY13 (1.01) to (0.23).
For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.
Shares of Incyte closed at $21.93 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins
- Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
